Avid Bioservices Inc (CDMO)

[biopharm]

I foresee PS Targeting and CDMO contracts increasing ...due to 3rd parties revealing that the IP was well worth the wait

As for Alzheimer's and all disease known to require an agent compound that easily slips pass the blood brain barrier ...there seems to be an extreme need for "surrogate endpoints" leading to MOS and those are being restricted by some that also have an extreme need for CDMO shares

I have to get all my Alzheimer's info together again ....as Biogen and PS Targeting may be making others wonder how this is aligned with Omeros that just validated that they are bringing up to date ..data ....to some conference

I guarantee that some will not want to be concerned about year end losses because Intercept has proven that once one is out...one is out of luck